Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for Step I:~* Confirmed diagnosis of HIV-1 infection~* Pregnant~* Between 14 and 35 weeks of gestation~* Documented platelet count of greater than 50,000 mm3 and an absolute neutrophil count (ANC) of greater than 500 mm3 within 28 days prior to study entry~* Able to understand and comply with planned study procedures~* On antiretroviral therapy (ART) as outlined in the treatment guidelines for pregnant HIV-1 infected women. Women must be currently taking ART or should initiate ART either prior to or concomitantly with the first dose of the vaccine.~Inclusion Criteria for Step II:~* Received the first dose of influenza A (H1N1) 2009 monovalent vaccine~* Has a documented platelet count of greater than 50,000 mm3 and an ANC of greater than 500 mm3 within the 28 days prior to Step II entry~Exclusion Criteria for Step I:~* Has a known allergy to eggs, egg products, neomycin, or polymyxin~* Has a history, in the opinion of the site investigator, of severe reactions following previous immunization with seasonal TIV~* Participation in a novel H1N1 influenza vaccine study in the past 2 years~* Proven history, by reverse transcription polymerase chain reaction (RT-PCR), of novel influenza H1N1 infection or positive influenza diagnostic test since June 2009 (specificity to H1N1 not required) prior to study entry~* Received any other live licensed vaccine within 4 weeks or inactivated licensed vaccine within 2 weeks prior to study entry~* Received a nonlicensed agent (vaccine, drug, biologic, device, blood product, or medication) within 4 weeks prior to vaccination in this study or expects to receive another nonlicensed agent before delivery~* Acute illness and/or an oral temperature greater than or equal to 100.0 degrees F within 24 hours prior to study entry~* Use of anti-cancer chemotherapy or radiation therapy within the preceding 36 months of study enrollment or has immunosuppression as a result of an underlying illness or treatment (other than HIV-1 infection)~* Active neoplastic disease (excluding nonmelanoma skin cancer, human papillomavirus \[HPV\]-related cervical dysplasia, and cervical intraepithelial neoplasia \[CIN\] Grades 1, 2, or 3)~* Long-term use of glucocorticoids, including oral or parenteral prednisone or equivalent (at least 2.0 mg/kg per day or at least 20 mg total dose) for more than 2 consecutive weeks (or 2 weeks total) in the past 3 months or high-dose inhaled steroids (more than 800 mcg/day of beclomethasone dipropionate or equivalent) within the past 3 months. Nasal and topical steroids are allowed.~* Received immunoglobulin or other blood products (with exception of Rho D immune globulin) within the 3 months prior to enrollment in this study~* Current diagnosis of uncontrolled major psychiatric disorder~* History of Guillain-Barre syndrome in the subject or subject's family (including parents, siblings, half-siblings, or children)~* Onset of a neurological disorder including (but not limited to) absent ankle and patellar deep tendon reflexes (DTRs) in both legs (all four absent) within the past 6 months~* Disproportionate loss of strength in lower extremity or extremities compared to the upper extremities (not thought to be related to pregnancy) within the past 6 months~* Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol. Pregnancy complications such as preterm labor, hypertension and pre-eclampsia are not exclusion criteria for this study.~Exclusion Criteria for Step II:~* Received a nonlicensed agent (vaccine, drug, biologic, device, blood product, or medication), other than from participation in this study, since the study vaccine dose #1 or expects to receive another nonlicensed agent before delivery~* Use of anti-cancer chemotherapy or radiation therapy since study vaccine dose #1, new diagnosis of an active malignancy, or is immunosuppressed as a result of an underlying illness (other than HIV-1 infection) or treatment~* Use of glucocorticoids, including oral or parenteral prednisone or equivalent (at least 2.0 mg/kg per day or at least 20 mg total dose) or high-dose inhaled steroids (more than 800 mcg/day of beclomethasone dipropionate or equivalent) for more than 2 consecutive weeks (or 2 weeks total) since study vaccine dose #1. Nasal and topical steroids are allowed.~* Received immunoglobulin or other blood products (with exception of Rho D immune globulin) since study vaccine dose #1~* A new diagnosis of uncontrolled major psychiatric disorder since study vaccine dose #1~* New occurrence or new awareness of Guillain-Barre syndrome in the subject or subject's family (including parents, siblings, half-siblings, or children) since study vaccine dose #1~* A new onset of a neurological disorder including (but not limited to) absent ankle and patellar DTRs in both legs (all four absent) since study vaccine dose #1~* Disproportionate loss of strength in lower extremity or extremities compared to the upper extremities (not thought to be related to pregnancy) since study vaccine dose #1~* Any Grade 3 toxicity or AE experienced by a participant unless the investigator has received protocol team approval~* Any Grade 4 toxicity or AE (other than injection site reaction or fever) that is definitely, probably, or possibly related to the study vaccine dose #1~* Any Grade 4 injection site reactions or fever experienced by a subject, unless the investigator has received protocol team approval~* Any Grade 4 AEs that are definitely not or probably not related to study vaccine, unless the investigator has received protocol team approval~* Any new clinical findings since the study vaccine dose #1, that, in the investigator's opinion, would compromise the safety of the participant~* Participant refuses further vaccination. The subject will still be asked to complete safety visits and be followed in the study.~* Participant withdraws consent. Participants may withdraw their consent for study participation at any time and for any reason, without penalty.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- H1N1 vaccine (Type: EXPERIMENTAL): Pregnant women enrolled received two doses of H1N1 vaccine, administered 21 days apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete